AKR1C3 as a target in castrate resistant prostate cancer
about
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerProstate Cancer Stem Cells: Research AdvancesTargeting the adaptive molecular landscape of castration-resistant prostate cancerStructures of complexes of type 5 17β-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor bindingOverexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiationThe Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequencesScreening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).Promiscuity and diversity in 3-ketosteroid reductases.The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer CellsPentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activitiesBerberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells5β-Reduced steroids and human Δ(4)-3-ketosteroid 5β-reductase (AKR1D1).Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.Combined transcriptome and metabolome analyses of metformin effects reveal novel links between metabolic networks in steroidogenic systems.Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model.In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).Androgen Signaling in Prostate Cancer.Rationale for the development of alternative forms of androgen deprivation therapy.Environmental factors and risk of aggressive prostate cancer among a population of New Zealand men - a genotypic approach.Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.Hormone whodunit: clues for solving the case of intratumor androgen production.Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis.Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry.Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
P2860
Q26777310-C4BFF42F-3909-4D18-AD13-84494FFC5D78Q26998435-DD1B7EA8-BCFE-48B8-B788-6580726C79F9Q27022821-007D6F59-D587-42B3-A9D7-429777808095Q27700118-23A25087-EBB5-44ED-B721-EA17B10ED9EAQ28817905-104EA708-95DB-4FC7-9464-5EC99B6DEB42Q33770742-75D89CCC-519B-4321-B584-8DB7F1E2AB5AQ34283623-2767ED42-7ED0-48C9-A780-363662D2BD4EQ35554014-92D4B829-1AA8-4566-85F4-D84952DB24D2Q35691232-B623BD0A-E799-4ACD-B535-05F24D20035FQ35978237-399C0C8B-7A94-4426-B671-90B7CBF7677AQ36142192-A7285838-F884-4F58-B784-A588CFAC8F68Q37113190-30F6AF7A-FF43-4E72-BE4A-7CF418F2E828Q37157965-C83CEFE0-58D8-4C10-A81D-883BC35BF4D0Q37677101-A5287174-8120-49F2-B500-D37A20251804Q37737611-EE5B1B36-C940-4D73-B67F-7FB7FE03E122Q38619155-57B81FFF-3B5A-416D-99F5-FF16BEF48885Q38735379-9530B0DE-7377-47B2-B179-45D37CCEAE9CQ38746249-F1537C3C-69E6-470D-9C04-97E004935C72Q38754094-D9C3753A-24E9-41C7-8DF6-5791D779BF3CQ38867044-9D54DFA1-B92B-49BF-AB5E-60139D9DAF40Q38979373-8F39D0B6-D377-492C-B9AC-47D5A589EFDFQ39227656-36C7865E-0BEC-4E7C-81E2-CCE94C26A878Q39342369-A33F86C9-8D7E-4FDD-87A0-A62BA4C6F163Q40311743-898DBE06-236A-4B54-965C-B42437988D60Q41872280-3EAA58D8-A6A9-4D74-933E-F7355905BB21Q42098076-58048EBE-D131-487E-AB7A-CE8D5DCC95CDQ42264659-3A9A5638-8ABB-4389-9F45-ECEF8BBC1298Q48251191-967926DB-6E22-4437-B946-4AAE25202F41Q51069851-023F31C4-5A51-4C76-B607-CF060B7B5825Q57694044-43F45861-DAFB-4C14-B835-FE32BF73477B
P2860
AKR1C3 as a target in castrate resistant prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
AKR1C3 as a target in castrate resistant prostate cancer
@en
AKR1C3 as a target in castrate resistant prostate cancer.
@nl
type
label
AKR1C3 as a target in castrate resistant prostate cancer
@en
AKR1C3 as a target in castrate resistant prostate cancer.
@nl
prefLabel
AKR1C3 as a target in castrate resistant prostate cancer
@en
AKR1C3 as a target in castrate resistant prostate cancer.
@nl
P2093
P2860
P1476
AKR1C3 as a target in castrate resistant prostate cancer
@en
P2093
Adegoke O Adeniji
Trevor M Penning
P2860
P304
P356
10.1016/J.JSBMB.2013.05.012
P577
2013-06-06T00:00:00Z